SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mkilloran who wrote (18054)1/22/1999 4:34:00 PM
From: VLAD  Read Replies (1) of 23519
 
martin,

The word I am getting is that Vivus will most likely end up partnering with Astra/Zeneca and will include Japan as part of this deal in order to make things most favorable for an eventual Astra/Zeneca buy out--perhaps as soon as this year. If Vivus partners with Astra/Zeneca and includes Japan in the agreement, then once Janssen's MUSE contract runs out Astra/Zeneca can take over their territory and have the entire world market to themselves including MUSE, Alibra, gene therapy and any other drug developed for intraurethral delivery.

The people at Astra will know exactly what the exclusive product rights will be worth to them in terms of potential global revenues from MUSE, Alibra, gene tx, etc.. They will be able to make good profits on the intraurethral therapies since their only costs will be the costs of production--they already have the sales force and administrative aspects in place.

For the above reasons, I am expecting Vivus to partner with Astra/Zeneca with the announcement coming some time in this quarter and an eventual buy out of vivus later in the year in a stock swap of Astra/Zeneca shares for Vivus shares. Astra/Zeneca will have an appreciation for the value of Vivus stock since they will have first hand knowledge of the profits generated in their respective markets which will include the United States. You can bet your Vivus investment that the take over value of Vivus will be much much higher than a lousy 2 11/16 a share.

BTW screw the market makers in this stock. They are all a bunch of thieves as has been proven in the latest SEC investigation/lawsuit.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News